Current in vitro Models to Study Drug-Induced Liver Injury

Hepatotoxicity: From Genomics to in vitro and in vivo Models

Volumn , Issue , 2008, Pages 1-55

  Davila, Julio C ^a   Xu, Jinghai J ^a   Hoffmaster, Keith A ^a   O'Brien, Peter J ^b,c   Storm, Stephen C ^d  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model predictability and dose dependency; Animal toxicity testing; Classic animal models; Drug induced liver injury (DILI); Enzyme induction and inhibition; Genetic and non genetic factors; Hepatotoxicity and cardiovascular toxicity; Idiosyncratic hepatotoxicity; Patient to patient variability; Recommended therapeutic dose

Indexed keywords

EID: 84889293305     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470516751.ch1     Document Type: Chapter

References (264)

1. Aden D. P., Fogel A., Plotkin S., Damjanov I. and Knowles B. B. (1979). Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 282:615-616.
2. Aithal G. P., Ramsay L., Daly A. K., Sonchit N., Leathart J. B. S., Alexander G.,Kenna J. G., Caldwell J. and Day C. P. (2004). Hepatic adducts, circulating antibodies and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430-1440.
3. Aligner A. (2006). Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Biotech 124:12-25.
4. Alison M. R., Poulsom R., Jeffery R., Dhillon A. P., Quaglia A., Jacob J., Novelli M., Prentice G., Williamson J. and Wright N. A. (2000). Hepatocytes from non-hepatic adult stem cells. Nature 406:257.
5. Allen J.W. and Bhatia S. N. (2003). Formation of steady-state oxygen gradients in vitro: application to liver zonation. Biotechnol Bioeng 82:253-262.
6. Allen J. W., Khetani S. R. and Bhatia S. N. (2005). In vitro zonation and toxicity in a hepatocyte bioreactor. Toxicol Sci 84:110-119.
7. Amacher D. E. and Martin B.-A. (1997). Tetracycline-Induced Steatosis in Primary Canine Hepatocyte Cultures. Fund Appl Toxicol 40:256-263.
8. Amin A. and Hanza A. A. (2005). Oxidative stress mediates drug-induced hepatotoxicity in rats: a possible role of DNA fragmentation. Toxicology 208:367-375.
9. Andrade R. J., Lucena M. I., Fernandez M. C., Pelaez G., Pachkoria K., Garcia-Ruiz E., Garcia-Munoz B., Gonzalez-Grande R., Pizarro A., Duran J. A., Jimenez M., Rodrigo L., Romero-Gomez M., Navarro J. M., Planas R., Costa J., Borras A., Soler A., Salmeron J. and Martin-Vivaldi R. (2005). Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129:512-521.
10. Aninat C., Piton A., Glaise D., Le Charpentier T., Langouet S., Morel F., Guguen-Guillouzo C. and Guillouzo A. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 34:75-83.
11. Asahina K., Fujimori H., Shimizu-Saito K., Kumashiro Y., Okamura K., Tanaka Y., Teramoto K., Arii S. and Teraoka H. (2004). Expression of the liver-specific gene Cyp7a1 reveals hepatic differentiation in embryoid bodies derived from mouse embryonic stem cells. Genes Cells 9:1297-1308.
12. Aurich I., Mueller L. P., Aurich H., Luetzkendorf J., Tisljar K., Dollinger M., SchormannW.,Walldorf J., Hengstler J., Fleig W. E. and Christ B. (2006). Functional integration of human mesenchymal stem cell-derived hepatocytes into mouse livers. Gut 56:405-415.
13. Avital I., Feraresso C., Aoki T., Hui T., Rozga J., Demetriou A. and Muraca M. (2002). Bone marrowderived liver stem cell and mature hepatocyte engraftment in livers undergoing rejection. Surgery 132:384-390.
14. Avital I., Inderbitzin D., Aoki T., Tyan D. B., Cohen A. H., Ferraresso C., Rozga J., ArnaoutW. S. and Demetriou A. A. (2001). Isolation, characterization, and transplantation of bone marrow-derived hepatocyte stem cells. Biochem Biophys Res Commun 288:156-164.
15. Bai J. and Cederbaum A. I. (2004). Adenovirus mediated overexpression of CYP2E1 increases sensitivity of HepG2 cells to acetaminophen induced cytotoxicity. Mol Cell Biochem 262:165-176.
16. Beerheide W., von Mach M. A., Ringel M., Fleckenstein C., Schumann S., Renzing N., Hildebrandt A., Brenner W., Jensen O., Gebhard S., Reifenberg K., Bender J., Oesch F. and Hengstler J. G. (2002). Downregulation of beta2-microglobulin in human cord blood somatic stem cells after transplantation into livers of SCID-mice: an escape mechanism of stem cells? Biochem Biophys Res Commun 294: 1052-1063.
17. Begriche K., Igoudjil A., Pessayre D. and Fromenty B. (2006). Mitochondrial dysfunction in NASH:causes, consequences and possible means to prevent it. Mitochondrion 6:1-28.
18. Begue J. M., Guguen-Guillouzo C., Pasdeloup N. and Guillouzo A. (1984). Prolonged maintenance of active CYP450 in adult rat hepatocytes co-cultured with another liver cell type. Hepatology 4:839-842.
19. Behlke M. A. (2006). Progress towards in vivo use of siRNAs. Mol Ther 13:644-670.
20. Berson A., Beco V. D., Letteron P., Robin M. A., Moreau C., Kahwaji J. E., Verthier N., Feldmann G., Fromenty B. and Pessayre D. (1998a). Steatohepatitis-Inducing Drugs Cause Mitochondrial Dysfuntion and Lipid Peroxidation in Rat Hepatocytes. Gastroenterology 114:764-774.
21. Berson A., De Beco V., Letteron P., Robin M. A., Moreau C., El Kahwaji J., Verthier N., Feldmann G., Fromenty B. and Pessayre D. (1998b). Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 114:764-774.
22. Berthiaume F., Moghe P. V., Toner M. and Yarmush M. L. (1996). Effect of extracellular matrix topology on cell structure, function and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J 10:1471-1484.
23. Biagini C., Bender V., Borde F., Boissel E., Bonnet M. C., Masson M. T., Cassio D. and Chevalier S. (2006a). Cytochrome P450 expression-induction profile and chemically mediated alterations of the WIF-B9 cell line. Biol Cell 98:23-32.
24. Biagini C. P., Boissel E., Borde F., Bender V. E., Bouskila M., Blazy F., Nicaise L., Mignot A., Cassio D. and Chevalier S. (2006b). Investigation of the hepatotoxicity profile of chemical entities using Liverbeads (R) and WIF-B9 in vitro models. Toxicol in Vitro 20:1051-1059.
25. Boelsterli U. A. (2003). Disease-related determinants of susceptibility to drug-induced idiosyncratic hepatotoxicity. Curr Opin Drug Discov Devel 6:81-91.
26. Bort R., Mace K., Boobis A., Gomez-Lechon M. J., Pfeifer A. and Castell J. (1999a). Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol 58:787-796.
27. Bort R., Ponsoda X., Jover R., Gomez-Lechon M. J. and Castell J. V. (1999b). Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 288:65-72.
28. Bova M. P., Tam D., McMahon G. and Mattson M. N. (2005). Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 155:41-50.
29. BowenW. P., Carey J., Miah A., McMurray H., Munday P., James R., Coleman R. and Brown A. M. (2000). Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polimerase chain reaction. Drug Metabol Dispos 28:781-788.
30. Bravo P., Bender V. and Cassio D. (1998). Efficient in vitro vectorial transport of a fluorescent conjugated bile acid analogue by polarized hepatic hybrid WIF-B and WIF-B9 cells. Hepatology 27:576-583.
31. Bull S., Langezaal I., Clothier R. and Coecke S. (2001). A Genetically engineered cell-based system for detecting metabolism-mediated toxicity. Altern Lab Anim 29:703-716.
32. Burchell B. and Coughtrie W. H. (1989). UDP-Glucuronosyltransferases. Pharmacol Ther 43:261-289.
33. Byrne J. A., Strautnieks S. S., Mieli-Vergani G., Higgins C. F., Linton K. J. and Thompson R. J. (2002). The human bile salt export pump: characterization of substrate specificity and identification of inhibitors. Gastroenterology 123:1649-1658.
34. Cantz T., Sharma A. D., Jochheim-Richter A., Arseniev L., Klein C., Manns M. P. and Ott M. (2004). Reevaluation of bone marrow-derived cells as a source for hepatocyte regeneration. Cell Transplant 13:659-666.
35. CareyM. A. and van Pelt F. N. (2005). Immunochemical detection of flucloxacillin adduct formation in livers of treated rats. Toxicology 216:41-48.
36. Castell J.V., Jover R., Martinez-Jimenez C. P. and Gomez-Lechon M. J. (2006). Hepatocyte cell lines:their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metabol Toxicol 2:183-212.
37. Cejka D., Losert D. and Wacheck V. (2006). Short interfering RNA (siRNA): tool or therapeutic? Clin Sci 110: 47-58.
38. Chen W. G., Zhang C., Avery M. J. and Fouda H. G. (2001). Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv Exp Med Biol 500:521-524.
39. Chen J., Yang X. X., Min H., Hu Z. P., He M., DuanW., Chan E., Cheu F. S., Chen X. and Zhou S. F. (2006). Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene. Drug Metabol Dispos 34, 1650-1657.
40. Choi E., Lee S., Yeom S., Kim G. H., Lee J. W. and Kim S.-W. (2005). Characterization of activating signal cointegrator-2 as a novel transcriptional coactivator of the xenobiotic nuclear receptor constitutive androstane receptor. Mol Endocrinol 19:1711-1719.
41. Crocenzi F. A., Mottino A. D., Sanchez Pozzi E. J., Pellegrino J. M., Rodriguez Garay E. A., Milkiewicz P., Vore M., Coleman R. and Roma M. G. (2003a). Impaired localisation and transport function of canalicular Bsep in taurolithocholate induced cholestasis in the rat. Gut 52:1170-1177.
42. Crocenzi F. A., Mottino A. D., Cao J., Veggi L. M., Pozzi E. J., Vore M., Coleman R. and Roma M. G. (2003b). Estradiol-17beta-d-glucuronide induces endocytic internalization of Bsep in rats. Am J Physiol Gastrointest Liver Physiol 285: G449-G459.
43. Cullen B. R. (2006). Induction of stable TNA interference in mammalian cells. Gene Ther 13:503-508.
44. Dan Y. Y., Riehle K. J., Lazaro C., Teoh N., Haque J., Campbell J. S. and Fausto N. (2006). Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci USA 103:9912-9917.
45. Davila J. C. and Morris D. L. (1999). Analysis of cytochrome P450 and Phase II conjugating enzyme expression in adult male rat hepatocytes. In vitro Cell Dev Biol 35:120-130.
46. Davila J. C., Rodrigues R. J., Melchert R. B. and Acosta D. (1998). Predicitive value of in vitro model systems in toxicology. Ann. Rev. Pharmacol. Toxicol 38:63-96.
47. Davila J. C., Cezar G. G., Thiede M., Strom S., Miki T. and Trosko J. (2004). Use and application of stem cells in toxicology. Toxicol Sci 79:214-223.
48. Debes J. D., Schmidt L. J., Huang H. and Tindall D. J. (2002). p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
49. Decaens C., Rodriguez P., Bouchaud C. and Cassio D. (1996). Establishment of hepatic cell polarity in the rat hepatoma-human fibroblast hybrid WIF-B9.Abiphasic phenomenon going from a simple epithelial polarized phenotype to an hepatic polarized one. J Cell Sci 109:1623-1635.
50. Diaz D. and O'Brien P. J. (2006). Defining the sequence of events in cerivastatin toxicity using a high content multi-parametric cytotoxicity assay. Eur Pharmaceut Rev 11:38-45.
51. Dillon C. P., Sandy P., Nencioni A., Kissler S., Rubinson D. A. and Van Parijs L. (2005). RNAi as an experimental and therapeutic tool to study and regulate physiological and disease processes. Annu Rev Physiol 67:147-173.
52. Donato M. T., Castell J., V. and Gomez-Lechon J. M. (1994). Cytochrome P450 activities in pure and co-cultured rat hepatocytes. Effects of model inducers. In vitro Cell Dev Biol 7:237-245.
53. Donato M. T., Castell J. V. and Gomez-Lechon J. M. (1995). Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary cultures. Drug Metabol Dispos 23:553-558.
54. Dunn J. C. Y., Tompkins R. G. and Yarmush M. L. (1991). Long term in vitro function of adult hepatocytes in a collagen sandwich configuration. Biotechnol Prog 7:237-245.
55. Dykxhoorn D. M. and Lieberman J. (2005). The silent revolution: RNA interference as basic biology, research tool and therapeutic. Annu Rev Med 56:401-423.
56. Dykxhoorn D. M., Palliser D. and Lieberman J. (2006). The silent treatment: siRNAs as small molecule drugs. Gene Ther 13:541-552.
57. Eaton D. L. and Bammler T. K. (1999). Consise review of the glutathione S-transferases and their significance to toxicity. Toxicol Sci 49:156-164.
58. Elkins S. and Wrighton S. A. (1999). The role of CYP2B6 in human xenobiotic metabolism. Drug Metabol Rev 31:719-754.
59. Enat R., Jefferson D. M. and Ruiz-Opazo N. (1984). Hepatocyte proliferation in vitro; its dependence on the use of serum-free hormonally defined medium and substrata of extrascellular matrix. Proc Natl Acad Sci USA 81:1411-1415.
60. Farkas D. and Tannembaum S. R. (2005). Characterization of chemically induced hepatotoxicity in collagen sandwiches of rat hepatocytes. Toxicol Sci 85:927-934.
61. Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B. and Meier P. J. (2001). The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223-231.
62. FDA (1999). In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis and Recommendations for Dosing and Labeling. [http://www.fda.gov/cder/guidance/2635fnl.pdf].
63. Fernandez C., Buyse M., German-Fattal M. and Gimenez F. (2004). Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 7:359-371.
64. Feuer G. and Di Fonzo C. J. (1992). Intrahepatic Cholestasis: A Review of Biochemical-Pathological Mechanisms. Drug Metab Drug Interact 10:1-161.
65. Fidkowski C., Kaazempur-Mofrad M. R., Borenstein J., Vacanti J. P., Langer R. andWang Y. (2005). Endothelialized microvasculature based on a biodegradable elastomer. Tissue Eng 11: 302-309.
66. Fiegel H. C., Lioznov M. V., Cortes-Dericks L., Lange C., Kluth D., Fehse B. and Zander A. R. (2003). Liver-specific gene expression in cultured human hematopoietic stem cells. Stem Cells 21:98-104.
67. Forbes S., Vig P., Poulsom R., Thomas H. and Alison M. (2002). Hepatic stem cells. J Pathol 197:510-518.
68. Fouin-Fortunet H., Letteron P., Tinel M., Degott C., Fish C. and Pessayre D. (1984). Mechanism for isaxonine hepatitis. II. Protective role of glutathione and toxicological studies in mice. J Pharmacol Exp Ther 229:851-858.
69. Fromenty B. and Pessayre D. (1995). Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Therapeut 67:101-154.
70. Fromenty B. and Pessayre D. (1997). Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 26(Suppl 2): 43-53.
71. Fromenty B., Robin M. A., Igoudjil A., Mansouri A. and Pessayre D. (2004). The ins and outs of mitochondrial dysfunction in NASH. Diabetes Metab 30:121-138.
72. Funk C., Ponelle C., Scheuermann G. and Pantze M. (2001). Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (BSEP) in the rat. Mol Pharmacol 59:627-635.
73. Gebhardt R., Hengstler J. G., Muller D., Glockner R., Buenning P., Laube B., Schmelz. E, Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B. R., Bader A., Langsch A., Koose T., Burger H., Mass J. and Oesch F. (2003). New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metabol Rev 35:145-213.
74. Gerlach J. C., Encke J., Hole O., Muller C., Ryan C. J. and Neuhaus P. (1994). Bioreactor for a larger scale hepatocyte in vitro perfusion. Transplantation 58:984-988.
75. Gerlach J. C., Schnoy N., Encke J., Smith M. D., Muller C. and Neuhaus P. (1995). Improved hepatocyte in vitro maintenance in a culture model with woven multicompartment capillary systems:electron microscopy studies. Hepatology 22:546-552.
76. Gerlach J. C., Mutig K., Sauer I. M., Schrade P., Efimova E., Mieder T., Naumann G., Grunwald A., Pless G., Mas A., Bachmann S., Neuhaus P. and Zeilinger K. (2003). Use of primary human liver cells originating from discarded grafts in a bioreactor for liver support therapy and the prospects of culturing adult liver stem cells in bioreactors: a morphologic study. Transplantation 76:781-786.
77. Giguere V. (1999). Orphan nuclear receptors: from gene to funciton. Endocrine Rev 20:689-725.
78. Gomez-Lechon M. J., Donato M. T., Castell J. V. and Jover R. (2004). Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr Drug Metabol 5:433-462.
79. Gonzalez F. (1996). The CYP2D6 Subfamily, Ioannides C, New York, NY, USA.
80. Gonzalez F. J. and Lee Y. H. (1996). Constitutive expression of hepatic cytochrome P450 genes. FASEB J 10:51-57.
81. Gradilone S. A., Tietz P. S., Splinter P. L., Marinelli R. A. and LaRusso N. F. (2005). Expression and subcellular localization of aquaporin water channels in the polarized hepatocyte cell line, WIF-B. BMC Physiol 5:13.
82. Guengerich F. (1997). Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 106:161-182.
83. Guillouzo A., Morel F., Langouet S., Maheo K. and Rissel. M. (1977). Use of hepatocytes for the study of hepatotoxic compounds. J Hepatol 26:73-80.
84. Gum R. J., Hickman D., Fagerland J. A., Heindel M. A., Gagne G. D., Schmidt J. M., Michaelides M. R., Davidsen S. K. and Ulrich R. G. (2001). Analysis ofTwo Matrix Metalloproteinase Inhibitors and Their Metabolites for Induction of Phospholipidosis in Rat and Human Hepatocytes. Biochem Pharmacol 62:1661-1673.
85. Hamilton G. A., Jolley S. L., Gilbert D., Coon D. J., Barros S. and LeCluyse E. L. (2001). Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 306:85-99.
86. Hannon G. and Rossi J. (2004). Unlocking the potential of the human genome with RNAi interference Nature 341: 371-378.
87. Hara Y., Sato Y., Yamamoto S., Nakatsuka H., Takeishi T., Hirano K., Kobayashi T., Watanabe T. and Hatakeyama K. (2003). Dispersion method of excessive portal hypertension (shear stress) and changes of portal pressure and flow after living-related liver transplantation with a splenorenal shunt: a case report. Transplant Proc 35:414-415.
88. Haroldsen P. E., Reilly M. H., Hughes H., Gaskell S. J. and Porter C. J. (1988). Characterization of glutathione conjugates by fast atom bombardment/tandem mass spectrometry. Biomed Environ Mass Spectrom 15:615-621.
89. Hartmann G., Cheung A. K. and Piquette-Miller M. (2002). Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J Pharmacol Exp Ther 303:273-281.
90. Haskins J. R., Rowse P., Rahbari R. and de la Iglesia F. A. (2001). Thiazolidinedione toxicity to isolated hepatocytes revealed by coherent multiprobe fluorescence microscopy and correlated with multiparameter flow cytometry of peripheral leukocytes. Arch Toxicol 75:425-438.
91. Hengstler J. G., Van Der Burg B., Steinberg P. and Oesch J. (1999). Interspecies differences in cancer susceptibility and toxicity. Drug Metabol Rev 31:917-970.
92. Hengstler J. G., Brulport M., SchormannW., Bauer A., Hermes M., Nussler A. K., Fandrich F., Ruhnke M., Ungefroren H., Griffin L., Bockamp E., Oesch F. and von Mach M. A. (2005). Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol 1:61-74.
93. Hines R. N. and McCarver D. G. (2002). The ontogeny of human drug-metabolizing enzymes:Phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
94. Hoebe K. H.,Witkamp R. F., Fink-Gremmels J., Van Miert A. S. and Monshouwer M. (2001). Direct cell-to-cell contact between Kupffer cells and hepatocytes augments endotoxin-induced hepatic injury. Am J Physiol Gastrointest Liver Physiol 280: G720-G728.
95. Hoffmaster K. A., Turncliff R. Z., LeCluyse E. L., Kim R. B., Meier P. J. and Brouwer K. L. (2004). P-glycoprotein expression, localization and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21:1294-1302.
96. Holt M. P. and Ju C. (2006). Mechanisms of drug-induced liver injury. AAPS J 8: E48-E54.
97. Ihrke G., Neufeld E. B., Meads T., Shanks M. R., Cassio D., Laurent M., Schroer T. A., Pagano R. E. and Hubbard A. L. (1993). WIF-B cells: an in vitro model for studies of hepatocyte polarity. J Cell Biol 123:1761-1775.
98. Ivanov M. A., Heuillet E., Vintezou P., Melcion C. and Cordier A. (1992). Primary Culture of Hepatocytes in the Investigation of Drug-Induced Steatosis, in G. Jolles and A. Cordier (eds), In Vitro Methods in Toxicology, Academic Press, New York, NY, USA, 165-187.
99. Jaeschke H. and Bajt M. L. (2006). Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci 89:31-41.
100. Jaeschke H., Gores G. J., Cederbaum A. I., Hinson J. A., Pessayre D. and Lemasters J. J. (2002a). Mechanisms of hepatotoxicity. Toxicol Sci 65:166-176.
101. Jungermann K. (1986). Functional heterogeneity of periportal and perivenous hepatocytes. Enzyme 35:161-180.
102. Kaihara S., Borenstein J., Koka R., Lalan S., Ochoa E. R., Ravens M., Pien H., Cunningham B. and Vacanti J. P. (2000). Silicon micromachining to tissue engineer branched vascular channels for liver fabrication. Tissue Eng 6:105-117.
103. Kakinuma S., Tanaka Y., Chinzei R.,Watanabe M., Shimizu-Saito K., Hara Y., Teramoto K., Arii S., Sato C., Takase K., Yasumizu T. and Teraoka H. (2003). Human umbilical cord blood as a source of transplantable hepatic progenitor cells. Stem Cells 21:217-227.
104. Kalgutkar A. S., Gardner I., Obach R. S., Shaffer C. L., Callegari E., Henne K. R., Mutlib A. E., Dalvie D. K., Lee J. S., Nakai Y., O'Donnell J. P., Boer J. and Harriman S. P. (2005). A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 6:161-225.
105. Kaplowitz N. (2002). Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 22:137-144.
106. Kaplowitz N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489-499.
107. Kawasaki T., Tamura S., Kiso S., Doi Y., Yoshida Y., Kamada Y., Saeki A., Saji Y. and Matsuzawa Y. (2005). Effects of growth factors on the growth and differentiation of mouse fetal liver epithelial cells in primary cultures. J Gastroenterol Hepatol 20:857-864.
108. Kessova I. G. and Cederbaum A. I. (2005). The effect of CYP2E1-dependent oxidant stress on activity of proteasomes in HepG2 cells. J Pharmacol Exp Ther 315:304-312.
109. Knasmuller S., Parzefall W., Sanyal R., Ecker S., Schwab C., Uhl M., Mersch-Sundermann V., Williamson G., Hietsch G., Langer T., Darroudi F. and Natarajan A. T. (1998). Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat Res 402:185-202.
110. Knasmuller S., Mersch-Sundermann V., Kevekordes S., Darroudi F., HuberW.W., Hoelzl C., Bichler J. and Majer B. J. (2004). Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. Toxicology 198:315-328.
111. Knowles B. B., Howe C. C. and Aden D. P. (1980). Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science 209:497-499.
112. Knowles S. R., Uetrecht J. and Shear N. H. (2000). Idiosyncratic Drug Reactions: the Reactive Metabolite Syndromes. Lancet 356:1587-1591.
113. Kocarek T. A., Schuetz E. G. and Guzelian P. S. (1992). Expression of multiple forms of cytochrome P450 mRNA in primary cultures of rat hepatocytes maintained on Matrigel. Mol Pharmacol 43:328-334.
114. KocarekT. A., Schuetz E. G., Strom S. C., Fisher R. A. and Guzelian P. S. (1995). Comparative analysis of cytochrome CYP3A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metabol Dispos 23:415-421.
115. Kogler G., Sensken S., Airey J. A., Trapp T., Muschen M., Feldhahn N., Liedtke S., Sorg R. V., Fischer J., Rosenbaum C., Greschat S., Knipper A., Bender J., Degistirici O., Gao J., Caplan A. I., Colletti E. J., Almeida-Porada G., Muller H. W., Zanjani E. and Wernet P. (2004). A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med 200:123-135.
116. Konieczko E. M., Ralston A. K., Crawford A. R., Karpen S. J. and Crawford J. M. (1998). Enhanced Na+-dependent bile salt uptake by WIF-B cells, a rat hepatoma hybrid cell line, following growth in the presence of a physiological bile salt. Hepatology 27:191-199.
117. Kostrubsky V. E., Strom S. C., Hanson J., Urda E., Rose K., Burliegh J., Zocharski P., Cai H., Sinclair J. F. and Sahi J. (2003). Evaluation of hepatotoxic potential of drugs by inhibition of bile-acid transport in cultured primary human hepatocytes and intact rats. Toxicol Sci 76:220-228.
118. Kostrubsky S. E., Strom S. C., Kalgutkar A. S., Kulkarni S., Atherton J., Mireles R., Feng B., Kubik R., Hanson J., Urda E. and Mutlib A. E. (2006). Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 90:451-459.
119. Krause D. S., Theise N. D., Collector M. I., Henegariu O., Hwang S., Gardner R., Neutzel S. and Sharkis S. J. (2001). Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell 105:369-377.
120. Kulig K. M. and Vacanti J. P. (2004). Hepatic tissue engineering. Transpl Immunol 12:303-310.
121. Lagasse E., Connors H., Al-Dhalimy M., Reitsma M., Dohse M., Osborne L.,Wang X., Finegold M., Weissman I. L. and Grompe M. (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med 6:1229-1234.
122. Larson A. M., Polson J., Fontana R. J., Davern T. J., Lalani E., Hynan L. S., Reisch J. S., Schiodt F. V., Ostapowicz G., Shakil A. O. and Lee W. M. (2005). Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364-1372.
123. Lautraite S., Bigot-Lasserre D., Bars R. and Carmichael N. (2003). Optimisation of cell-based assays for medium throughput screening of oxidative stress. Toxicol in Vitro 17:207-220.
124. Lavon N. and Benvenisty N. (2005). Study of hepatocyte differentiation using embryonic stem cells. J Cell Biochem 96:1193-1202.
125. Lavon N., Yanuka O. and Benvenisty N. (2004). Differentiation and isolation of hepatic-like cells from human embryonic stem cells. Differentiation 72:230-238.
126. Le Vee M., Jigorel E., Glaise D., Gripon P., Guguen-Guillouzo C. and Fardel O. (2006). Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur J Pharm Sci 28:109-117.
127. LeBel C. P., Ischiropoulos H. and Bondy S. C. (1992). Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem Res Toxicol 5:227-231.
128. LeCluyse E. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharm. Sci. 13:343-368.
129. LeCluyse E. L., Audus K. L. and Hochman J. H. (1994). Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am J Physiol 266: C1764-C1774.
130. LeCluyse E. L., Bullock P. L. and Parkinson A. (1996). Strategies for restoration and maintenance of normal hepatic structure and function in long-term cultures of rat hepatocytes. Adv Drug Deliv Rev 22:133-186.
131. LeCluyse E. L., Alexandre E., Hamilton G. A., Viollon-Abadie C., Coon D. J., Jolley S. and Richert L. (2005). Isolation and culture of primary human hepatocytes. Meth Mol Biol 290:207-229.
132. Lee S. H. and Sinko P. J. (2006). siRNA-getting the message out. Eur J Pharm Sci 27:401-410.
133. Lee W. M. (2003). Drug-induced hepatotoxicity. New Engl J Med 349:474-485.
134. Lengyel G., Veres Z., Szabo P., Vereczkey L. and Jemnitz K. (2005). Canalicular and sinusoidal disposition of bilirubin mono-and diglucuronides in sandwich-cultured human and rat primary hepatocytes. Drug Metab Dispos 33:1355-1360.
135. Letteron P., Sutton A., Mansouri A., Fromenty B. and Pessayre D. (2003). Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 38:133-140.
136. Lewis D. F. V., Ioannides C. and Park D. V. (1998). Cytochrome P450 and species differences in xenobiotic metabolism and activation of carcinogens. Environ Health Perspect 106:633-641.
137. Li T. and Chiang J. Y. (2006). Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metabol Dispos 34:756-764.
138. Lilius H., Haestbacka T. and Isomaa B. (1996). A combination of fluorescent probes for evaluation of cytotoxicity and toxic mechanisms in isolated rainbow trout hepatocytes. Toxicol in Vitro 10:341-348.
139. Liu X., Chism J. P., LeCluyse E. L., Brouwer K. R. and Brouwer K. L. (1999). Correlation of biliary excretion in sandwich-cultured rat hepatocytes and in vivo in rats. Drug Metab Dispos 27:637-644.
140. Lu P. Y., Xie F. and Woodle M. C. (2006). In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 54:117-142.
141. Luo G., Guenthner T., Gan L. S. and Humphreys W. G. (2004). CYP3A4 induction by xenobiotics:biochemistry, experimental methods and impact on drug driscovery an develeopment. Curr Drug Metabol 5:483-505.
142. Mace K., Aguilar F., Wang J. S., Vautravers P., Gomez-Lechon M., Gonzalez F. J., Groopman J., Harris C. C. and Pfeifer A. M. (1997). Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. Carcinogenesis 18:1291-1297.
143. Maenpaa J., Rane A., Raunio H., Honkakoski P. and Pelkonen O. (1993). Cytochrome P450 isoforms in human fetal tissues related to phenobarbital-inducible forms in the mouse. Biochem Pharmacol 45:899-907.
144. Malhi H., Gores G. J. and Lemasters J. J. (2006). Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43: S31-S44.
145. Manov I., Hirsh M. and Iancu T. C. (2002). Acetaminophen hepatotoxicity and mechanisms of its protection by N-acetylcysteine: a study of Hep3B cells. Exp Toxicol Pathol 53:489-500.
146. Marschall H. U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., Silbert D., Fuchsbichler A., Benthin L., Grundstrom R., Gustafsson U., Sahlin S., Einarsson C. and Trauner M. (2005). Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129:476-485.
147. McCarthy T. C., Pollak P. T., Hanniman E. A. and Sinal C. J. (2004). Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J Pharmacol Exp Ther 311:864-873.
148. McMillian M. K., Grant E. R., Zhong Z., Parker J. B., Li L., Zivin R. A., Burczynski M. E. and Johnson M. D. (2001). Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In vitro Mol Toxicol 14:177-190.
149. McRae M. P., Lowe C. M., Tian X., Bourdet D. L., Ho R. H., Leake B. F., Kim R. B., Brouwer K. L. and Kashuba A. D. (2006). Ritonavir, Saquinavir and Efavirenz, but not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes. J Pharmacol Exp Ther 318:1068-1075.
150. Mehendale H. M. (2005).Tissue repair: an important determinant of final outcome of toxicant-induced injury. Toxicol Pathol 33: 41-51.
151. Micheline D., Emmanuel J. and Serge E. (2002). Effect of Ursodeoxycholic Acid on the Expression of the Hepatocellular Bile Acid Transporters (Ntcp and bsep) in Rats with Estrogen-Induced Cholestasis. J Pediatr Gastroenterol Nutr 35:185-191.
152. Miki T., Lehmann T., Cai H., Stolz D. B. and Strom S. C. (2005). Stem Cell Characteristics of Amniotic Epithelial Cells. Stem Cells 23:1549-1559.
153. Mimura M, Baba T, Yamazaki H, Ohmori S, Inui Y, Gonzalez F. J, Guengerich F.P. and Shimada T. (1993). Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metabol Dispos. 2:1048-1056.
154. Minagawa M., Deng Q., Liu Z. X., Tsukamoto H. and Dennert G. (2004). Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-alpha during alcohol consumption. Gastroenterology 126:1387-1399.
155. Mita S., Suzuki H., Akita H., Hayashi H., Onuki R., Hofmann A. F. and SugiyamaY. (2006). Inhibition of bile acid transport acrossNTCPand BSEP co-expressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab Dispos 34:1575-1581.
156. Miyazaki M., Akiyama I., Sakaguchi M., Nakashima E., Okada M., Kataoka K. and Huh N. H. (2002). Improved conditions to induce hepatocytes from rat bone marrow cells in culture. Biochem Biophys Res Commun 298:24-30.
157. Miyazaki M., MasakaT., Akiyama I., Nakashima E., Sakaguchi M. and Huh N. H. (2004). Propagation of adult rat bone marrow-derived hepatocyte-like cells by serial passages in vitro. Cell Transplant 13:385-391.
158. Motomura W., Inoue M., Ohtake T., Takahashi N., Nagamine M., Tanno S., Kohgo Y. and Okumura T. (2006). Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun 340:1111-1118.
159. Neuman M. G., Koren G. and Tiribelli C. (1993). In vitro assessment of the ethanol-induced hepatotoxicity on HepG2 cell line. Biochem Biophys Res Commun 197:932-941.
160. Newsome P. N., Johannessen I., Boyle S., Dalakas E., McAulay K. A., Samuel K., Rae F., Forrester L., Turner M. L., Hayes P. C., Harrison D. J., Bickmore W. A. and Plevris J. N. (2003). Human cord blood-derived cells can differentiate into hepatocytes in the mouse liver with no evidence of cellular fusion. Gastroenterology 124:1891-1900.
161. Noe J., Stieger B. and Meier P. J. (2002). Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123:1659-1666.
162. Nonome K., Li X. K., Takahara T., KitazawaY., Funeshima N.,YataY., Xue F., Kanayama M., Shinno E.,Kuwae C., Saito S.,Watanabe A. and Sugiyama T. (2005). Human umbilical cord blood-derived cells differentiate into hepatocyte-like cells in the Fas-mediated liver injury model. Am J Physiol Gastrointest Liver Physiol 289: G1091-G1099.
163. Nowak G., Ericzon B. G., Nava S., Jaksch M., Westgren M. and Sumitran-Holgersson S. (2005). Identification of expandable human hepatic progenitors which differentiate into mature hepatic cells in vivo. Gut 54: 972-979.
164. O'Brien P. J. and Haskins J. R. (2006). In vitro cytotoxicity assessment, in K. Guiliano, D. Lansing Taylor and J. R. Haskins (eds), High-Content Screening: A Powerful Approach to Systems Cell Biology and Drug Discovery, Human a Press, Totowa, NJ, USA, 415-425.
165. O'Brien P. J., Kalow B. I., Ali N., Lassaline L. A. and Lumsden J. H. (1990). Compensatory increase in calcium extrusion activity of untreated lymphocytes from swine susceptible to malignant hyperthermia. Am J Vet Res 51:1038-1043.
166. O'Brien P. J., IrwinW., Diaz D.,Howard-Cofield E., Krejsa C. M., Slaughter M. R., Gao B., Kaludercic N., Angeline A., Bernardi P., Brain P. and Hougham C. (2006). High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. Arch Toxicol 80:580-604.
167. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B. and Heller A. (2000). Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulat Toxicol Pharmacol 32:56-67.
168. Omiecinski C. J., Redlich C. A. and Costa P. (1990). Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res 50:4315-4321.
169. Ostapowicz G., Fontana R. J., Schiodt F. V., Larson A., Davern T. J., Han S. H., McCashland T. M., Shakil A. O., Hay J. E., Hynan L., Crippin J. S., Blei A. T., Samuel G., Reisch J. and Lee W. M. (2002). Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137:947-954.
170. Pang K. S., Schwab A. J., Goresky C. A. and Chiba M. (1994). Transport, binding and metabolism of sulfate conjugates in the liver. Chem Biol Interact 92:179-207.
171. Park B. K., Naisbitt D. J., Gordon S. F., Kitteringham N. R. and Pirmohamed M. (2001). Metabolic activation in drug allergies. Toxicology 158:11-23.
172. Park K.,Williams D. P., Naisbitt D. J., Kitteringham N. R. and Pirmohamed M. (2005). Investigation of toxic metabolites during drug development. Toxicol Appl Pharmacol 207:425-434.
173. Pearson P. G., Threadgill M. D., Howald W. N. and Baillie T. A. (1988). Applications of tandem mass spectrometry to the characterization of derivatized glutathione conjugates. Studies with S-(N-methylcarbamoyl)glutathione, a metabolite of the antineoplastic agent N-methylformamide. Biomed Environ Mass Spectrom 16:51-56.
174. Peraza M. A., Burdick A. D., Marin H. E., Gonzalez F. J. and Peters J. M. (2006). The toxicology of ligands for peroxisome proliferators-activated receptors (PPAR). Toxicol Sci 90:269-295.
175. Pessayre D. (1995). Role of reactive metabolites in drug-induced hepatitis. J Hepatol 23: S16-S24.
176. Peters T. (2005). Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol Pathol 33: 146-154.
177. Petersen B. E., Bowen W. C., Patrene K. D., Mars W. M., Sullivan A. K., Murase N., Boggs S. S., Greenberger J. S. and Goff J. P. (1999). Bone marrow as a potential source of hepatic oval cells. Science 284:1168-1170.
178. Pfeifer A. M., Cole K. E., Smoot D. T., Weston A., Groopman J. D., Shields P. G., Vignaud J. M., Juillerat M., Lipsky M. M., Trump B. F., Lechner J. F. and Harris C. C. (1993). Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens. Proc Natl Acad Sci USA 90:5123-5127.
179. Pichler A., Zelcer N., Prior J. L., Kuil A. J. and Piwnica-Worms D. (2005). In vivo RNA interferencemediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 11:4487-4494.
180. Pirmohamed M., Naisbitt D. J., Gordon F. and Park B. K. (2002). The danger hypothesis-potential role in idiosyncratic drug reactions. Toxicology 181/182: 55-63.
181. Plass J. R. M., Mol O., Heegsma J., Geuken M., Faber K. N., Jansen P. L. M. and Muller M. (2002). Farsenoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35:589-596.
182. Powers M. J., Domansky K., Kaazempur-Mofrad M. R., Kalezi A., Capitano A., Upadhyaya A., Kurzawski P., Wack K. E., Stolz D. B., Kamm R. and Griffith L. G. (2002a). A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng 78:257-269.
183. Powers M. J., Janigian D. M., Wack K. E., Baker C. S., Beer Stolz D. and Griffith L. G. (2002b). Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng 8:499-513.
184. Prough R. A., Xiao G. H. and Falkner K. C. (1996). Hormonal regulation of hepatic enzymes involved in foreign compound metabolism. FASEB J 10:1369-1377.
185. Rainsford K. D., Seabrook R.W., Spencer S. and Hewson A. T. (2001). Effects of nimesulide and its metabolites or manufacturing intermediates on the viability and growth of the human hepatoma HepG2 cell line. Life Sci 69:2965-2973.
186. Rambhatla L., Chiu C. P., Kundu P., Peng Y. and Carpenter M. K. (2003). Generation of hepatocytelike cells from human embryonic stem cells. Cell Transplant 12:1-11.
187. Reid A. B., Kurten R. C., McCullough S. S., Brock R. W. and Hinson J. A. (2005). Mechanisms of acetaminophen-induced hepatotoxicity: role of oxidative stress and mitochondrial permeability transition in freshly isolated mouse hepatocytes. J Pharmacol Exp Ther 312:509-516.
188. Renton K.W. (2004). Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 5:235-243.
189. Richert L., Binda D., Hamilton G. A., Viollon-Abadie A. E., Bigot-Lasserre D., Bars R., Coasssolo P. and LeCluyse E. (2002). Evaluation of the effect of culture configuration on morphology, survival time, antioxidant status and metabolic capabilities of cultured rat hepatocytes. Tox in Vitro 16:89-99.
190. Richert L., Liguori M., Abadie C., Heyd B., Mantion G., Khalkic N. and Waring J. F. (2006). Gene expression in human hepatocytes in suspension after isolation is similar to the liver in origin, is not affected by hepatocyte cold storage and cryopreservation, but is strongly changed after hepatocyte plating. Drug Metabol Dispos 34:870-879.
191. Roberts R. (1999). Peroxisome proliferators: mechanisms of adverse effects in rodents and molecular basis for species differences. Arch Toxicol 73:413-418.
192. Robin M. A., Maratrat M., Le Roy M., Le Breton F. P., Bonierbale E., Dansette P., Ballet F., Mansuy D. and Pessayre D. (1996). Antigenic targets in tienilic acid hepatit. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 98:1471-1480.
193. Roman I. D., Fernandez-Moreno M. D., Fueyo J. A., Roma M. G. and Coleman R. (2003). Cyclosporin A induced internalization of the bile salt export pump in isolated rat hepatocyte couplets. Toxicol Sci 71:276-281.
194. Ruhnke M., Nussler A. K., Ungefroren H., Hengstler J. G., Kremer B., HoeckhW., GottwaldT., Heeckt P. and Fandrich F. (2005a). Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 79:1097-1103.
195. Ruhnke M., Ungefroren H., Nussler A., Martin F., Brulport M., Schormann W., Hengstler J. G., Klapper W., Ulrichs K., Hutchinson J. A., Soria B., Parwaresch R. M., Heeckt P., Kremer B. and Fandrich F. (2005b). Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 128:1774-1786.
196. Saad B., Scholl F. A., Thomas H., Schawalder H., Streit V., Waechter F. and Maier P. (1993). Crude liver membrane fractions and extracellular matrix components as substrata regulate differentially the preservation and inducibility of cytochrome P-450 isoenzymes in cultured rat hepatocytes. Eur J Biochem 213:805-814.
197. Sahi J. (2005). Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Exp Opin 1:409-427.
198. Saji Y., Tamura S., Yoshida Y., Kiso S., Iizuka A. S., Matsumoto H., Kawasaki T., Kamada Y., Matsuzawa Y. and Shinomura Y. (2004). Basic fibroblast growth factor promotes the transdifferentiation of mouse bone marrow cells into hepatic lineage cells via multiple liver-enriched transcription factors. J Hepatol 41:545-550.
199. Sanderson J. P., Naisbitt D. J. and Park B. K. (2006). Role of bioactivation in drug-induced hypersensitivity reactions. AAPS J 8: E55-E64.
200. SatoY.,Koyama S., Tsukada K. and Hatakeyama K. (1997). Acute portal hypertension reflecting shear stress as a trigger of liver regeneration following partial hepatectomy. Surg Today 27:518-526.
201. Sato Y., Tsukada K. and Hatakeyama K. (1999). Role of shear stress and immune responses in liver regeneration after a partial hepatectomy. Surg Today 29:1-9.
202. Sawada H., Takami K. and Asahi S. (2005). A toxicogenomic approach to drug-induced phospholipidosis:analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 83:282-292.
203. Schaffert C. S., Todero S. L., McVicker B. L., Tuma P. L., Sorrell M. F. and Tuma D. J. (2004). WIF-B cells as a model for alcohol-induced hepatocyte injury. Biochem Pharmacol 67:2167-2174.
204. Schmelzer E., Wauthier E. and Reid L. M. (2006). The phenotypes of pluripotent human hepatic progenitors. Stem Cells 24:1852-1858.
205. Schuetz E. G., Curtiss D. L., Omiecinski C. J., Mueller-Eberhard U., Kleinman H. K., Elswick B. and Guzelian P. S. (1988). Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix. J Cell Physiol 134:309-323.
206. Schuetz E. G., Schmid W., Schutz G., Brimer C., Yasuda K., Kamataki T., Bornhrim L., Myles K. and Cole T. J. (2000). The glucocorticoid receptor is essential for induction of cytochrome P450B by steroids but not for drug or steroid induction of CYP3A or P450 reductase in mouse liver. Drug Metabol Dispos 28:268-366.
207. Schuetz J. D., Beach D. L. and Guzelian P. S. (1994). Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 4:11-20.
208. Schuster D., Laggner C. and Langer T. (2005). Why drugs fail-a study on side effects in new chemical entities. Curr Pharm Des 11:3545-3559.
209. Schwabe R. F. and Brenner D. A. (2006). Mechanisms of Liver Injury. I. TNF-alpha-induced liver injury: role of IKK, JNK and ROS pathways. Am J Physiol Gastrointest Liver Physiol 290: G583-G589.
210. Schwartz R. E., Reyes M., Koodie L., Jiang Y., Blackstad M., Lund T., Lenvik T., Johnson S., Hu W. S. andVerfaillie C. M. (2002). Multipotent adult progenitor cells from bone marrowdifferentiate into functional hepatocyte-like cells. J Clin Invest 109:1291-1302.
211. Shankar P., Manjunath N. and Lieberman J. (2005). The prospect of silencing disease using RNA interference. JAMA 293:1367-1373.
212. Shanks M. R., Cassio D., Lecoq O. and Hubbard A. L. (1994). An improved polarized rat hepatoma hybrid cell line. Generation and comparison with its hepatoma relatives and hepatocytes in vivo. J Cell Sci 107:813-825.
213. Sharma A. D., Cantz T., Richter R., Eckert K., Henschler R., Wilkens L., Jochheim-Richter A., Arseniev L. and Ott M. (2005). Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver. Am J Pathol 167:555-564.
214. Shimada T., Yamazaki H., Mimura M.,Wakamiya N., Ueng Y. F., Guengerich F. P. and Inui Y. (1996). Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos 24:515-522.
215. Shirahashi H.,Wu J., Yamamoto N., Catana A.,Wege H.,Wager B., Okita K. and Zern M. A. (2004). Differentiation of human and mouse embryonic stem cells along a hepatocyte lineage. Cell Transpl 13:197-211.
216. Sidhu J. S., Farin F. M. and Kavanagh T. J. (1994). Effect of tissue-culture substratum and extracellular matrix overlay on liver-selective and xenobiotic inducible gene expression in primary rat hepatocytes In Vitro Toxicol 7: 225-242.
217. Silva J. M., Morin P. E., Day S. H., Kennedy B. P., Payetter P., Rushmore T., Yergey J. A. and Nicoll-Griffith D. A. (1998). Refinement of an in vitro cell model for cytochrome P450 induction. Drug Metabol Dispos 26:490-496.
218. Sinz M. W. and Kim S. (2006). Stem cells, immortalized cells and primary cells in ADMET assays. Drug Discov Technol 3:79-85.
219. Sivaraman A., Leach J. K., Townsend S., Iida T., Hogan B. J., Stolz D. B., Fry R., Samson L. D., Tannenbaum S. R. and Griffith L. G. (2005). A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6:569-591.
220. Slaughter M. R., Thakkar H. and O'Brien P. J. (2002). Effect of diquat on the antioxidant system and cell growth in human neuroblastoma cells. Toxicol Appl Pharmacol 178:63-70.
221. Sledz C. A. andWilliams B. R. (2005). RNAinterference in biology and disease. Blood 106: 787-794.
222. Smith C. M., Graham R. A., KrolW. L., Silver I. S., Negishi M.,Wang H. and Lecluyse E. L. (2005). Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells. J Pharmacol Exp Ther 315:1256-1264.
223. Song E., Lee S.-K.,Wang J., Ince N., Ouyang N., Min J., Chen J., Shankar P. and Lieberman J. (2003). RNA interference targeting Fas protects mice from fulminant hepatitits. Nature Med 9:347-351.
224. Sonnier M. and Cresteil T. (1998). Delayed ontogenesis of CYP1A2 in the human liver. Eur J Biochem 251:893-898.
225. Soto-Gutierrez A., Navarro-Alvarez N., Rivas-Carrillo J. D., Chen Y., Yamatsuji T., Tanaka N. and Kobayashi N. (2006). Differentiation of human embryonic stem cells to hepatocytes using deleted variant of HGF and poly-amino-urethane-coated nonwoven polytetrafluoroethylene fabric. Cell Transpl 15:335-341.
226. Stevens J. C., Hines R. N., Gu C., Koukouritaki S. B., Manro J. R., Tandler P. J. and Zaya M. J. (2003). Developmental expression of the major human hepatic CYP3A enzymes. J Pharmacol Exp Ther 307:573-582.
227. Stieger B., Fattinger K., Madon J., Kullak-Ublick G. A. and Meier P. J. (2000). Drug-and estrogeninduced cholestasis through inhibition of the hepatocellular bile salt export pump (BSEP) of rat liver. Gastroenterology 118:422-430.
228. Strom S. C., Pisarov L. A., Dorko K., Thompson M. T., Schuetz J. D. and Schuetz E. G. (1996). Use of human hepatocytes to study P450 gene induction. Meth Enzymol 272:388-401.
229. Tam Y. K. (1993). Individual variation in first-pass metabolism. Clin Pharmacokinet 25:300-328.
230. Tan N. S., Michalik L., Desvergne B. andWahliW. (2005). Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol 93:99-105.
231. Tateishi T., Nakura H., Asoh M.,Watanabe M., Tanaka M.,Kumai T., Takashima S., Imaoka S., Funae Y., Yabusaki Y., Kamataki T. and Kobayashi S. (1997). A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy. Life Sci 61:2567-2574.
232. Tay V. K., Wang A. S., Leow K. Y., Ong M. M., Wong K. P. and Boelsterli U. (2005). Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med 39:949-959.
233. Teramoto K., Asahina K., Kumashiro Y., Kakinuma S., Chinzei R., Shimizu-Saito K., Tanaka Y., Teraoka H. and Arii S. (2005). Hepatocyte differentiation from embryonic stem cells and umbilical cord blood cells. J Hepatobil Pancreat Surg 12:196-202.
234. Thompson D. C., Barhoumi R. and Burghard R. C. (1998). Comparative toxicity of eugenol and its quinone methide metabolite in cultured liver cells using kinetic fluorescence bioassays. Toxicol Appl Pharmacol 149:55-63.
235. Tian X., Zamek-Gliszczynski J., Zhang P. and Brower K. L. R. (2004). Modulation of multidrug resistance-associated protein 2 (Mrp2) and Mrp3 expression and function with small interfering RNA in sandwich-cultured rat hepatocytes. Mol Pharmacol 66:1004-1010.
236. Tosh D., Shen C. N. and Slack J. M. (2002). Differentiated properties of hepatocytes induced from pancreatic cells. Hepatology 36:534-543.
237. Tuschl G. and Mueller S. O. (2006). Effects of cell culture conditions on primary rat hepatocytes-cell morphology an differential gene expression. Toxicology 218:205-215.
238. Vassilopoulos G.,Wang P. R. and Russell D.W. (2003). Transplanted bone marrow regenerates liver by cell fusion. Nature 422:901-904.
239. Vignati L. A., Bogni A., Grossi P. and Monshouwer M. (2004). A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology 199:23-33.
240. Vignati L., Turlizzi E., Monaci S., Grossi P., Kanter R. and Monshouwer M. (2005). An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology 216:154-167.
241. Wagers A. J., Sherwood R. I., Christensen J. L. and Weissman I. L. (2002). Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 297:2256-2259.
242. Walkup M. H. and Gerber D. A. (2006). Hepatic stem cells: in search of. Stem Cells 24:1833-1840.
243. Wang H. and Joseph J. A. (1999). Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27:612-616.
244. Wang K., Shindoh H., Inoue T. and Horii I. (2002). Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J Toxicol Sci 27:229-237.
245. Wang X., Willenbring H., Akkari Y., Torimaru Y., Foster M., Al-Dhalimy M., Lagasse E., Finegold M., Olson S. and Grompe M. (2003). Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature 422:897-901.
246. Waring J. F., Ciurlionis R., Jolly R. A., Heindel M., Gagne G., Fagerland J. A. and Ulrich R. G. (2003). Isolated human hepatocytes in culture display markedly different gene expression patterns depending on atachment status. Tox in Vitro 17:693-701.
247. Waxman D. J., Pampori N. A. and Ram P. (1991). Interpulsive interval in circulating growth hormone patterns regulates sexually dimorphic expression of hepatic cytochrome P450. Biochem J 88:6868-6872.
248. Wilkening S., Stahl F. and Bader A. (2003). Comparison of primary human hepatocytes and hepatoma cell line HepG2 with regard to their biotransformation properties. Drug Metab Dispos 31:1035-1042.
249. Willenbring H., Bailey A. S., Foster M., Akkari Y., Dorrell C., Olson S., Finegold M., Fleming W. H. and Grompe M. (2004). Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nature Med 10:744-748.
250. Wormhoudt L. W., Commandeur J. N. M. and Vermeulen N. P. E. (1999). Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-s-tranferase, and epoxide hydrolase enzymes: Relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124.
251. Wright M. E., M.J. T. and Aebersold R. (2003). Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 17:1726-1737.
252. Wrighton S. A., Molowa D. T. and Guzelian P. S. (1988). Identification of a cytochrome P-450 in human fetal liver related to glucocorticoid-inducible cytochrome P-450HLp in the adult. Biochem Pharmacol 37:3053-3055.
253. Xie W., Barwick J. L., Downes M., Blumberg B., Simon C. M., Nelson M. C., Neuschwander-Tetri B. A., Brunt E. M., Guzelian P. S. and Evans R. M. (2000). Humanized xenobiotic respnse in mice expressing nuclear receptor SXR. Nature 406:435-439.
254. Xu Y., Bradham C., Brenner D. A. and Czaja M. J. (1997). Hydrogen peroxide-induced liver cell necrosis is dependent on AP-1 activation. Am J Physiol 273: G795-G803.
255. Xu J. J., Diaz D. and O'Brien P. J. (2004). Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150:115-128.
256. Xu D., McCarty D., Fernandes A., Fisher M., Samulski R. J. and Juliano R. L. (2005). Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-associated virus vector. Mol Ther 11:523-530.
257. Yamaguchi K., Itoh K., Masuda T., Umemura A., Baum C., Itoh Y., Okanoue T. and Fujita J. (2006). In vivo selection of transduced hematopoietic stem cells and little evidence of their conversion into hepatocytes in vivo. J Hepatol 45:681-687.
258. Yang H. Y., Lee Q. P., Rettie A. E. and Juchau M. R. (1994). Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol Pharmacol 46:922-928.
259. Yoon H. G., Chan D. W., Huang Z. Q., Li J., Fondell J. D., Qin J. and Wong J. (2003). Purification and functional characterization of the human N-CoR complex: the roles of HDAC3, TBL1 and TBLR1. Embo J 22:1336-1346.
260. Zeilinger K., Auth S., Unger J., Grebe A., Mao L., Petrik M., Holland G., Appel K., Nussler A., Neuhaus P. and Gerlach J. (2000). Liver cell culture in bioreactors for in vitro drug studies as an alternative to animal testing. Altex 17:3-10.
261. Zeilinger K., Sauer I. M., Pless G., Strobel C., Rudzitis J., Wang A., Nussler A. K., Grebe A., Mao L., Auth S. H., Unger J., Neuhaus P. and Gerlach J. C. (2002). Three-dimensional co-culture of primary human liver cells in bioreactors for in vitro drug studies: effects of the initial cell quality on the long-term maintenance of hepatocyte-specific functions. Altern Lab Anim 30:525-538.
262. Zeilinger K., Holland G., Sauer I. M.,Efimova E., Kardassis D., Obermayer N., Liu M., Neuhaus P. and Gerlach J. C. (2004). Time course of primary liver cell reorganization in three-dimensional highdensity bioreactors for extracorporeal liver support: an immunohistochemical and ultrastructural study. Tissue Eng 10:1113-1124.
263. Zhang Z. Y., Pelletier R. D., Wong Y. N., Sugawara M., Zhao N. and Littlefield B. A. (2006). Preferential inducibility of CYP1A1 and CYP1A2 by TCDD: differential regulation in primary human hepatocytes versus transformed human cells. Biochem Biophys Res Commun 341:399-407.
264. Zhou G., Hashimoto Y., Kwak I., Tsai S. Y. and Tsai M. J. (2003). Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742-7755.